iOrganBio, a company specializing in intelligent cell manufacturing, announced the appointment of Zhiping Pang, M.D., Ph.D., to its Scientific Advisory Board. Dr. Pang is a Henry Rutgers Professor of NeuroMetabolism and Professor of Neuroscience and Cell Biology at Rutgers Robert Wood Johnson Medical School, and Director of the Center for NeuroMetabolism at Rutgers Health. With over 140 publications in top journals such as Nature, Science, Nature Neuroscience, and Nature Metabolism, he brings expertise in human neuron biology, synaptic function, and the molecular mechanisms underlying neuropsychiatric and metabolic disorders.
The appointment bolsters iOrganBio's scientific leadership as the field moves toward more human-relevant, non-animal systems. The company's CellForge™ platform uses AI and automation to guide cell development, making real-time adjustments aligned with defined biological profiles. At its core is the functional human CellAtlas™, a comprehensive reference built from single-cell and multi-omics data that provides digital blueprints for each cell type. This closed-loop process aims to deliver accuracy, efficiency, and quality for disease modeling, regenerative medicine, and drug development.
Dr. Pang's expertise in human neuron biology is particularly relevant as iOrganBio focuses on FDA-aligned New Approach Methodologies (NAMs), which aim to replace or reduce animal testing with human-relevant in vitro models. His insights could accelerate the development of scalable human cell and organoid production for research and therapeutic applications. The company's AI-powered platform is designed to produce cells and organoids consistently, addressing a critical bottleneck in the translation of scientific discoveries into clinical applications.
The addition of Dr. Pang to the Scientific Advisory Board underscores iOrganBio's commitment to advancing intelligent cell manufacturing. As the industry increasingly adopts non-animal systems, the company's technology could play a pivotal role in improving the predictability of drug development and reducing reliance on animal models. This news matters because it highlights the convergence of AI, cell biology, and regulatory science, which has the potential to reshape how therapeutics are developed and tested.
For more information about iOrganBio and its CellForge platform, visit iOrgan.Bio.
